--- title: "CANbridge to Raise HK$199 Million via Discounted Share Subscription Backed by WuXi Biologics Unit" description: "CANbridge Pharmaceuticals Inc. has announced a subscription agreement to issue 84,033,613 new shares at HK$2.38 each, raising approximately HK$199 million. The shares will be sold to a Hong Kong limit" type: "news" locale: "en" url: "https://longbridge.com/en/news/276015318.md" published_at: "2026-02-15T22:37:12.000Z" --- # CANbridge to Raise HK$199 Million via Discounted Share Subscription Backed by WuXi Biologics Unit > CANbridge Pharmaceuticals Inc. has announced a subscription agreement to issue 84,033,613 new shares at HK$2.38 each, raising approximately HK$199 million. The shares will be sold to a Hong Kong limited partnership owned by WuXi Biologics, at a discount to market prices. Proceeds will be used for working capital, R&D, and settling trade payables. The transaction is subject to regulatory approval and reflects ongoing support from WuXi Biologics. The latest analyst rating for CANbridge stock is a Buy with a target price of HK$3.00. ### President's Day Sale - 70% Off - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential An announcement from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available. CANbridge Pharmaceuticals has entered into a subscription agreement to issue 84,033,613 new shares at HK$2.38 per share to a Hong Kong limited partnership indirectly wholly owned by WuXi Biologics. The pricing represents a discount to recent market prices, and the listing of these subscription shares on the Hong Kong Stock Exchange is subject to regulatory approval. The share sale is expected to raise approximately HK$199 million in net proceeds, which CANbridge plans to use for working capital and registration maintenance of commercialized products, research and development of its existing pipeline, and settlement of group trade payables. The transaction, which remains conditional on the fulfillment or waiver of certain conditions, underscores ongoing strategic financial support from a major biologics contract research and manufacturing player. The most recent analyst rating on (HK:1228) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page. **More about CANbridge Pharmaceuticals Inc.** CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics, with a portfolio that includes commercialized products and a pipeline of drug candidates. The company operates in the healthcare and life sciences sector, with a focus on biopharmaceutical innovation and related research and development activities. **Average Trading Volume:** 3,434,975 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$1.43B For an in-depth examination of 1228 stock, go to TipRanks’ Overview page. ### Related Stocks - [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md) - [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md) - [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md) - [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md) - [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md) - [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md) - [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md) - [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md) - [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md) - [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink | WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not alr | [Link](https://longbridge.com/en/news/275670240.md) | | ImmuneOnco Biopharmaceuticals Grants RMB13.7 Million Loan to Executive Chairman | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has granted a loan of RMB13.7 million to its executive chairman, Dr. Tian | [Link](https://longbridge.com/en/news/275465718.md) | | AsymBio Launches Integrated Biopharma Platforms for End-to-End Development | AsymBio, a subsidiary of Asymchem Laboratories Tianjin Co. Ltd., has launched integrated technology platforms for the en | [Link](https://longbridge.com/en/news/275471539.md) | | Niowave and Novartis enter global actinium-225 Supply Agreement to advance next-generation cancer therapies | Niowave and Novartis enter global actinium-225 Supply Agreement to advance next-generation cancer therapies | [Link](https://longbridge.com/en/news/275604614.md) | | Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.